|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HOXA7 |
Gene summary for HOXA7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HOXA7 | Gene ID | 3204 |
| Gene name | homeobox A7 | |
| Gene Alias | ANTP | |
| Cytomap | 7p15.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P31268 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3204 | HOXA7 | LZE2T | Human | Esophagus | ESCC | 4.68e-07 | 6.34e-01 | 0.082 |
| 3204 | HOXA7 | LZE4T | Human | Esophagus | ESCC | 3.20e-12 | 3.97e-01 | 0.0811 |
| 3204 | HOXA7 | LZE7T | Human | Esophagus | ESCC | 1.29e-05 | 4.28e-01 | 0.0667 |
| 3204 | HOXA7 | LZE8T | Human | Esophagus | ESCC | 1.26e-02 | 1.26e-01 | 0.067 |
| 3204 | HOXA7 | LZE20T | Human | Esophagus | ESCC | 3.04e-04 | 1.68e-01 | 0.0662 |
| 3204 | HOXA7 | LZE22T | Human | Esophagus | ESCC | 1.17e-04 | 4.22e-01 | 0.068 |
| 3204 | HOXA7 | LZE24T | Human | Esophagus | ESCC | 1.96e-16 | 3.73e-01 | 0.0596 |
| 3204 | HOXA7 | LZE21T | Human | Esophagus | ESCC | 6.00e-05 | 3.47e-01 | 0.0655 |
| 3204 | HOXA7 | LZE6T | Human | Esophagus | ESCC | 2.44e-05 | 2.93e-01 | 0.0845 |
| 3204 | HOXA7 | P1T-E | Human | Esophagus | ESCC | 5.07e-10 | 5.22e-01 | 0.0875 |
| 3204 | HOXA7 | P2T-E | Human | Esophagus | ESCC | 2.52e-31 | 4.59e-01 | 0.1177 |
| 3204 | HOXA7 | P4T-E | Human | Esophagus | ESCC | 1.07e-38 | 9.63e-01 | 0.1323 |
| 3204 | HOXA7 | P5T-E | Human | Esophagus | ESCC | 1.45e-09 | 1.66e-01 | 0.1327 |
| 3204 | HOXA7 | P8T-E | Human | Esophagus | ESCC | 3.44e-23 | 3.88e-01 | 0.0889 |
| 3204 | HOXA7 | P9T-E | Human | Esophagus | ESCC | 1.94e-22 | 5.59e-01 | 0.1131 |
| 3204 | HOXA7 | P10T-E | Human | Esophagus | ESCC | 7.38e-51 | 8.55e-01 | 0.116 |
| 3204 | HOXA7 | P12T-E | Human | Esophagus | ESCC | 2.84e-37 | 7.06e-01 | 0.1122 |
| 3204 | HOXA7 | P15T-E | Human | Esophagus | ESCC | 1.36e-21 | 4.85e-01 | 0.1149 |
| 3204 | HOXA7 | P16T-E | Human | Esophagus | ESCC | 4.14e-24 | 4.99e-01 | 0.1153 |
| 3204 | HOXA7 | P17T-E | Human | Esophagus | ESCC | 3.24e-04 | 1.88e-01 | 0.1278 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003022416 | Esophagus | ESCC | monocyte differentiation | 25/8552 | 36/18723 | 3.39e-03 | 1.39e-02 | 25 |
| GO:00487052 | Esophagus | ESCC | skeletal system morphogenesis | 120/8552 | 220/18723 | 4.90e-03 | 1.89e-02 | 120 |
| GO:000276115 | Esophagus | ESCC | regulation of myeloid leukocyte differentiation | 69/8552 | 120/18723 | 6.00e-03 | 2.21e-02 | 69 |
| GO:000268515 | Esophagus | ESCC | regulation of leukocyte migration | 114/8552 | 210/18723 | 7.26e-03 | 2.63e-02 | 114 |
| GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
| GO:001081029 | Thyroid | ATC | regulation of cell-substrate adhesion | 128/6293 | 221/18723 | 8.74e-14 | 4.57e-12 | 128 |
| GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
| GO:0001952110 | Thyroid | ATC | regulation of cell-matrix adhesion | 78/6293 | 128/18723 | 2.09e-10 | 6.15e-09 | 78 |
| GO:003009933 | Thyroid | ATC | myeloid cell differentiation | 170/6293 | 381/18723 | 4.26e-06 | 4.68e-05 | 170 |
| GO:004886321 | Thyroid | ATC | stem cell differentiation | 97/6293 | 206/18723 | 3.88e-05 | 3.15e-04 | 97 |
| GO:00487053 | Thyroid | ATC | skeletal system morphogenesis | 101/6293 | 220/18723 | 9.48e-05 | 6.93e-04 | 101 |
| GO:004001316 | Thyroid | ATC | negative regulation of locomotion | 160/6293 | 391/18723 | 1.36e-03 | 7.07e-03 | 160 |
| GO:000716225 | Thyroid | ATC | negative regulation of cell adhesion | 127/6293 | 303/18723 | 1.45e-03 | 7.47e-03 | 127 |
| GO:003033616 | Thyroid | ATC | negative regulation of cell migration | 142/6293 | 344/18723 | 1.64e-03 | 8.22e-03 | 142 |
| GO:005127117 | Thyroid | ATC | negative regulation of cellular component movement | 150/6293 | 367/18723 | 1.99e-03 | 9.54e-03 | 150 |
| GO:200014617 | Thyroid | ATC | negative regulation of cell motility | 147/6293 | 359/18723 | 2.01e-03 | 9.60e-03 | 147 |
| GO:00485688 | Thyroid | ATC | embryonic organ development | 172/6293 | 427/18723 | 2.08e-03 | 9.84e-03 | 172 |
| GO:000268519 | Thyroid | ATC | regulation of leukocyte migration | 90/6293 | 210/18723 | 3.11e-03 | 1.40e-02 | 90 |
| GO:1903706112 | Thyroid | ATC | regulation of hemopoiesis | 148/6293 | 367/18723 | 3.87e-03 | 1.68e-02 | 148 |
| GO:0045637113 | Thyroid | ATC | regulation of myeloid cell differentiation | 89/6293 | 210/18723 | 4.75e-03 | 1.96e-02 | 89 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| HOXA7 | MVA | Cervix | CC | CFAP20,CCL23,INHBB, etc. | 1.38e-02 |  |
| HOXA7 | ICAF | Cervix | HSIL_HPV | CFAP20,CCL23,INHBB, etc. | 2.99e-02 |  |
| HOXA7 | MYOFIB | Endometrium | Healthy | GPBAR1,INAFM2,APTR, etc. | 1.94e-01 |  |
| HOXA7 | MSC | Esophagus | Healthy | SFRP4,HOXB7,HOXA5, etc. | 1.30e-02 |  |
| HOXA7 | MSC.PVA | Skin | cSCC | ZBED5,MOSPD1,KLC2, etc. | 1.88e-02 |  |
| HOXA7 | LYMEND | Skin | SCCIS | ZBED5,MOSPD1,KLC2, etc. | 1.72e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HOXA7 | SNV | Missense_Mutation | novel | c.475N>T | p.Arg159Cys | p.R159C | P31268 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
| HOXA7 | SNV | Missense_Mutation | c.542G>A | p.Arg181His | p.R181H | P31268 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| HOXA7 | insertion | Frame_Shift_Ins | novel | c.439_440insGGACAATTCTTCTCTCGGGCTGCCCAAGCGACAGCTGTCAG | p.Lys147ArgfsTer23 | p.K147Rfs*23 | P31268 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| HOXA7 | insertion | Frame_Shift_Ins | novel | c.425_426insCGAGGGCGCCGTGCCCTCTGCCGCCGCCACT | p.Leu143GlufsTer30 | p.L143Efs*30 | P31268 | protein_coding | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| HOXA7 | SNV | Missense_Mutation | rs755438662 | c.89C>T | p.Ser30Phe | p.S30F | P31268 | protein_coding | deleterious(0) | possibly_damaging(0.592) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| HOXA7 | SNV | Missense_Mutation | novel | c.589N>A | p.Ala197Thr | p.A197T | P31268 | protein_coding | tolerated(0.78) | benign(0) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HOXA7 | SNV | Missense_Mutation | novel | c.526N>C | p.Ile176Leu | p.I176L | P31268 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| HOXA7 | SNV | Missense_Mutation | novel | c.479G>A | p.Arg160His | p.R160H | P31268 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HOXA7 | SNV | Missense_Mutation | c.497N>T | p.Ala166Val | p.A166V | P31268 | protein_coding | tolerated(0.08) | possibly_damaging(0.663) | TCGA-DC-6157-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| HOXA7 | SNV | Missense_Mutation | c.550N>G | p.Lys184Glu | p.K184E | P31268 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |